As the RNA Oncology Company, TransCode is committed to defeating cancer through the intelligent design and effective delivery of regulatory and messenger RNA. Our modular toolbox enables rational drug design, exemplified by our lead Therapeutic Candidate TTX-MC138 which targets miR-10b for the treatment of metastatic cancer. Research & Development efforts are focused on expanding our delivery capabilities in RNAi as well as RIG-I, CRISPR, and mRNA.
Publicly Traded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):